195 related articles for article (PubMed ID: 21826062)
1. MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.
Ramakrishnan V; Ansell S; Haug J; Grote D; Kimlinger T; Stenson M; Timm M; Wellik L; Halling T; Rajkumar SV; Kumar S
Leukemia; 2012 Feb; 26(2):340-8. PubMed ID: 21826062
[TBL] [Abstract][Full Text] [Related]
2. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
3. Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells.
Tanaka S; Nakada M; Yamada D; Nakano I; Todo T; Ino Y; Hoshii T; Tadokoro Y; Ohta K; Ali MA; Hayashi Y; Hamada J; Hirao A
J Neurooncol; 2015 Jan; 121(2):239-50. PubMed ID: 25293440
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitory effects of gamma secretase inhibitor on human multiple myeloma xenograft mouse model].
Liu QQ; Liu JL; Guo DM; Teng QL
Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):794-7. PubMed ID: 24103879
[TBL] [Abstract][Full Text] [Related]
5. Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade.
Chu Q; Orr BA; Semenkow S; Bar EE; Eberhart CG
Clin Cancer Res; 2013 Jun; 19(12):3224-33. PubMed ID: 23630166
[TBL] [Abstract][Full Text] [Related]
6. Notch signaling promotes growth and invasion in uveal melanoma.
Asnaghi L; Ebrahimi KB; Schreck KC; Bar EE; Coonfield ML; Bell WR; Handa J; Merbs SL; Harbour JW; Eberhart CG
Clin Cancer Res; 2012 Feb; 18(3):654-65. PubMed ID: 22228632
[TBL] [Abstract][Full Text] [Related]
7. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.
Kondratyev M; Kreso A; Hallett RM; Girgis-Gabardo A; Barcelon ME; Ilieva D; Ware C; Majumder PK; Hassell JA
Oncogene; 2012 Jan; 31(1):93-103. PubMed ID: 21666715
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.
Jazirehi AR; Bonavida B
Mol Cancer Ther; 2004 Jan; 3(1):71-84. PubMed ID: 14749477
[TBL] [Abstract][Full Text] [Related]
9. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
Timme CR; Gruidl M; Yeatman TJ
Apoptosis; 2013 Oct; 18(10):1163-74. PubMed ID: 23887890
[TBL] [Abstract][Full Text] [Related]
10. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.
Cook N; Frese KK; Bapiro TE; Jacobetz MA; Gopinathan A; Miller JL; Rao SS; Demuth T; Howat WJ; Jodrell DI; Tuveson DA
J Exp Med; 2012 Mar; 209(3):437-44. PubMed ID: 22351932
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.
Li M; Chen F; Clifton N; Sullivan DM; Dalton WS; Gabrilovich DI; Nefedova Y
Mol Cancer Ther; 2010 Dec; 9(12):3200-9. PubMed ID: 21159606
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.
Lewis HD; Leveridge M; Strack PR; Haldon CD; O'neil J; Kim H; Madin A; Hannam JC; Look AT; Kohl N; Draetta G; Harrison T; Kerby JA; Shearman MS; Beher D
Chem Biol; 2007 Feb; 14(2):209-19. PubMed ID: 17317574
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
15. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
Jazirehi AR; Gan XH; De Vos S; Emmanouilides C; Bonavida B
Mol Cancer Ther; 2003 Nov; 2(11):1183-93. PubMed ID: 14617792
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
Tammam J; Ware C; Efferson C; O'Neil J; Rao S; Qu X; Gorenstein J; Angagaw M; Kim H; Kenific C; Kunii K; Leach KJ; Nikov G; Zhao J; Dai X; Hardwick J; Scott M; Winter C; Bristow L; Elbi C; Reilly JF; Look T; Draetta G; Van der Ploeg L; Kohl NE; Strack PR; Majumder PK
Br J Pharmacol; 2009 Nov; 158(5):1183-95. PubMed ID: 19775282
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
20. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
